| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ANIP | Common Stock | Sale | -$1.18M | -20K | -2.85% | $58.90 | 683K | Jun 21, 2024 | Held by Esjay LLC | F1, F2, F3 |
| holding | ANIP | Common Stock | 68.7K | Jun 21, 2024 | Direct | ||||||
| holding | ANIP | Common Stock | 5K | Jun 21, 2024 | Held by SS Pharma LLC | F4 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. |
| F2 | The shares were sold in multiple trades at prices ranging from $58.43 to $59.48. The price reported above reflects the weighted average sales price. |
| F3 | The reporting person holds voting and dispositive power over the shares held by Esjay LLC. |
| F4 | The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC. |